Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human EPO/Erythropoietin Protein, 20µg  

Recombinant Human EPO/Erythropoietin Protein, 20µg

Recombinant Human EPO /Erythropoietin Protein, Native (rhEPO) Ala28-Arg193 was expressed in human 293 cells (HEK293)

Synonyms: EPO, EP, MVCD2, Erythropoietin, Erythropoetin, Erthropoyetin, Hematopoietin, Hemopoietin, Erythropoietin Protein

More details

EPO-H4214-020

Availability: within 7 days

238,00 €

Background: Human Erythropoietin (EPO) is also known as EP, erythropoetin or erthropoyetin, and is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. EPO is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. is synthesized by renal peritubular cells in adults, with a small amount being produced in the liver.[1-2] Regulation is believed to rely on a feed-back mechanism measuring blood oxygenation. Constitutively synthesized transcription factors for EPO, known as hypoxia-inducible factors (HIFs), are hydroxylated and proteosomally digested in the presence of oxygen.[3] It binds to the erythropoietin receptor (EpoR) on the red cell surface and activates a JAK2 cascade. Erythropoietin has its primary effect on red blood cells by promoting red blood cell survival through protecting these cells from apoptosis. It also cooperates with various growth factors involved in the development of precursor red cells. EPO has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. It has also been shown that erythropoietin can increase iron absorption by suppressing the hormone hepcidin.[4] Erythropoietin has been shown to interact with the Erythropoietin receptor as its mechanism of action within the body.[5] erythropoietin plays an important role in the brain\'s response to neuronal injury. EPO is also involved in the wound healing process.[6].

Source
Recombinant Human EPO /Erythropoietin Protein, Native (rhEPO) Ala28-Arg193 (Accession# AAH93628.1) was expressed in human 293 cells (HEK293).

Molecular Characterization
rhEPO has a calculated MW of 18.4 kDa. DTT-reduced protein migrates as 30-37 kDa estimated polypeptide in SDS-PAGE resulting from glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhEPO by the LAL method.

Purity
>97% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization. 

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
The bio-activity was determined by dose-dependent stimulation of the proliferation of TF-1 cells. The specific activity measured is more than 1.2X105 Unit/mg.


References

(1) Jacobson LO, et al., 1957, Nature 179 (4560): 633–4.
(2) Fisher JW, et al., 1996, British journal of haematology 95 (1): 27–32.
(3) Jelkmann W ., 2007, Eur. J. Haematol. 78 (3): 183–205.
(4) Ashby DR, et al., 2010, Haematologica 95 (3): 505–8.
(5) Middleton S A., 1999, J. Biol. Chem. (UNITED STATES) 274 (20): 14163–9.
(6) Haroon ZA, et al., 2003, Am. J. Pathol. 163 (3): 993–1000.